This is a working overview of aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
== Prognosis == Proper treatment of SAAM often results in full recovery. Recovery can occur even with persistently elevated creatine kinase (CK) levels. Conversely, some people with SAAM do not regain full muscle strength despite the normalization of their CK levels. Longitudinal analysis of a patient cohort revealed that the majority of patients (85%) over 60 years old recovered full strength within four years, compared to less than half of patients below 52 years old, indicating that age during disease onset may be an important prognostic determinant. Once strength recovers, immunosuppressive medications should be tapered. Relapse remains possible during tapering efforts, and some people require long-term immunosuppression. An affected person is more likely to experience permanent muscle damage if they do not receive adequate treatment for a long time. Muscle weakness occurs due to the replacement of some muscle with fatty tissue.
There is disagreement over whether MRI should be the diagnostic tool of choice. Magnetic resonance imaging is less effective than CT at directly imaging sites of CSF leak. MRI studies may show pachymeningeal enhancement (when the dura mater looks thick and inflamed), sagging of the brain, pituitary enlargement, subdural hygromas, engorgement of cerebral venous sinuses, and other abnormalities. For 20% of patients, MRIs present as completely normal. MRIs performed with the patient seated upright (vs. laying supine) are not better for diagnosing CSF leaks, but are more than twice as effective at diagnosing cerebellar tonsillar ectopia, also known as Chiari malformation. Cerebellar tonsillar ectopia shares many of the same symptoms as CSF leak, but originates either congenitally or from trauma, including whiplash strain to the dura. An alternate method of locating the site of a CSF leak is to use heavily T2-weighted MR myelography. This has been effective in identifying the sites of a CSF leak without the need for a CT scan, lumbar puncture, and contrast and at locating fluid collections such as CSF pooling. Another highly successful method of locating a CSF leak is intrathecal contrast and MR myelography. Contrast-enhanced brain MRI with sagittal reformats can assess for the following:
Creatine-alpha-ketoglutarate is a salt formed from alpha-ketoglutaric acid (AKG) and creatine. Creatine is a mass-produced fitness supplement that is supposed to increase the user's muscle mass, strength and power. Creatine requires a delivery system for cell uptake. An example is arginine alpha-ketoglutarate. Arginine alpha-ketoglutarate itself is a chemical compound that is supposed to increase the blood flow to muscles and therefore, increase nutrient delivery to muscle cells. Alpha-ketoglutarate (α-KG or AKG) itself is a central molecule in the Krebs cycle that controls the organism's overall citric acid cycle rate. It can improve bone tissue development in the skeletal muscles by decreasing protein catabolism and increasing protein synthesis. The supplement industry has theorized that binding creatine to alpha-ketoglutarate could show significant improvements in creatine delivery and uptake which would ultimately lead to greater improvements in muscle mass and performance. Still relatively new in the fitness industry, more research is needed to test the validity of its effects.
Sources: en.wikipedia.org
There are also small-molecule medications that provide temporary relief. Before Onpattro was released, the treatment options for hATTR were limited. After the approval of Onpattro, the FDA awarded Alnylam with the Breakthrough Therapy Designation, which is given to drugs that are intended to treat a serious condition and are a substantial improvement over any available therapy. It was also awarded Orphan Drug Designations given to those treatments that are intended to safely treat conditions affecting fewer than 200,000 people. Along with Onpattro, another RNA interference therapeutic drug, patisiran, has also been developed, which has the property of inhibiting hepatic synthesis of transthyretin. As a result, target messenger RNA (mRNA) is cleaved by small interfering RNAs coupled to the RNA-induced silencing complex. Patisiran, an RNAi therapeutic drug, uses this process to decrease the production of mutant and wild-type transthyretin by cleaving the 3' untranslated region of transthyretin mRNA. In 2019, the FDA approved the second RNAi therapy, Givlaari (givosiran), used to treat acute hepatic porphyria (AHP). The disease is caused by the accumulation of toxic porphobilinogen (PBG) molecules, which are formed during the production of heme. These molecules accumulate in different organs, and this can lead to the symptoms or attacks of AHP. Givlaari is an siRNA drug that downregulates the expression of aminolevulinic acid synthase 1 (ALAS1), a liver enzyme involved in an early step in heme production.
=== Subtypes of bone sarcoma === Osteosarcoma Chondrosarcoma Poorly differentiated round/spindle cell tumors (includes Ewing sarcoma) Hemangioendothelioma Angiosarcoma Fibrosarcoma/myofibrosarcoma Chordoma Adamantinoma Other: Liposarcoma Leiomyosarcoma Malignant peripheral nerve sheath tumor Rhabdomyosarcoma Synovial sarcoma Malignant solitary fibrous tumor.
=== Preparation of the metal === Einsteinium is highly reactive, so strong reducing agents are required to obtain the pure metal from its compounds. This can be achieved by reduction of einsteinium(III) fluoride with metallic lithium:
These genes encode a variety of well established PIDDosome components and significant signaling proteins, including PIDD1, CRADD, CASP2, p53, and cyclin-dependent kinase inhibitor 1A (CDKN1A, often referred to as p21). They also encompass four proteins not previously associated with PIDDosome signaling: centrosomal protein 20 (CEP20, also known as FOPNL), C2 domain-containing protein 3 (C2CD3), which is involved in centriole elongation, sodium channel and clathrin linker 1 (SCLT1), and ankyrin repeat domain 26 (ANKRD26). The ability of these proteins to inhibit the proliferation of cells overexpressing PLK4 was confirmed through competition assays, underscoring their important functions in cell cycle regulation. Inadequate centrosome clustering resulted in a reduced activation of the PIDDosome, as shown by diminished CASP2 activation and lower p21 levels in RPE-1 cells with PLK4 overexpression and absent ANKRD26. Further experiments, involving both ANKRD26-competent and -deficient RPE-1 cells along with various full-length proteins, mutants lacking specific domains, and non-cleavable variants, demonstrated that PIDD1's recruitment to centrioles is mediated by the interaction between the acidic region of ANKRD26 and the UPA domain of the C-terminal part of PIDD1 (PIDD1-CC), which arises from PIDD1's autoproteolytic processing. Importantly, in the context of inducible PLK4, this interaction was critical for the activation of the PIDDosome and the resulting cell cycle arrest.
Sources: en.wikipedia.org
Because reporter genes such as lacZ, GFP, and luciferase are widely used in standardized plasmid constructs for gene expression studies, well-characterized reporter vectors are preserved as reference materials in public biological resource centres and non-profit repositories such as BCCM/GeneCorner and Addgene, supporting reproducibility in molecular biology research.
=== Composition and selectivity === Condensate components are usually divided into scaffolds, which drive phase separation, and clients, which do not phase separate on their own but can still be recruited into the dense phase. Client recruitment depends on the number of available binding sites as well as the valency and affinity of the client, so changes in scaffold stoichiometry can alter the composition of the condensate. Partitioning is also influenced by physical factors that are distinct from specific binding. Because condensates consist of dense networks of intrinsically disordered regions (IDRs), inserting a molecule restricts the conformational freedom of the surrounding chains, resulting in an entropic penalty that increases with particle size. Calculations combined with coarse-grained modelling show that the free energy of insertion increases with both IDR density and particle size, and becomes dependent on particle surface area once the particle is larger than the network mesh size. At typical IDR concentrations, particles as small as 4 nm in diameter can be almost entirely excluded, with approximately 97% exclusion in the absence of favourable interactions with condensate components.
=== 1992 === 9 August The Triumph of the Embryo, it showed how the egg divides, and the chemical signals involved that direct the growing mass of cells; at the start, cell division takes place every 12–15 hours; four days later the embryo reaches the uterus, with about sixty cells; cells moved due to peptide growth factors (peptide hormones; growth is regulated by homeobox genes, a method discovered in 1983 by William McGinnis and Michael Levine; Corey Goodman of the Howard Hughes Medical Institute, and how nerve cells grew; the role of glia cells, described by Colin Blakemore; Lewis Wolpert of UCL; Douglas A. Melton. Narrated by Alun Lewis, directed by Yavar Abbas, produced by Geoff Deehan, made by Union Pictures 16 August The Siege of Barcelona, a behind-the-scenes view of how Barcelona prepared for the 25th Summer Olympic Games, and the technical innovations in filming the events.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.